Since it remains unknown what percentage of patients who receive Zytiga before Provenge will remain symptomatic after Zytiga therapy, there is risk that, if used before Provenge, Zytiga could shrink the eligible patient population for Provenge.

FORBES: Dendreon Takes Another Hit: This Time, Thanks To Johnson & Johnson